Cardiotoxicity of First-line Therapies for Advanced Prostate Cancer

Dr Moez Karim Aziz, MD, MSc is a PGY-3 internal medicine resident physician at Baylor College of Medicine, Houston, US. He graduated from University of Pennsylvania with a dual degree in biophysics and bioengineering. He completed his master’s degree in electrical and computer engineering from the Georgia Institute of Technology and received his medical degree from the University of Texas Health Science Center at Houston McGovern Medical School.

Dr Aziz has conducted research in cardiology and cardio-oncology for over 10 years; his work has been published in journals including Circulation, Frontiers in Cardiovascular Medicine, and, most recently, European Urology. His research has traversed basic and translational science of cardiomyocyte metabolomics, cardiovascular bioelectronics, and, more recently, cardio-oncology clinical research. While a medical student, Dr Aziz developed a model for stent healing in cancer patients with cardiovascular comorbidities in collaboration with MD Anderson Cancer Center.

While a resident, he founded and chaired the PROXMAP study, an international initiative designed to systematically profile cardiotoxicity of first-line therapies for advanced states of prostate cancer. He plans to pursue cardiology fellowship.

Dr Steven E. Canfield, MD is the C.R. Bard, Edward J. McGuire, MD Distinguished Chair, Professor and Chief of Urology at the University of Texas McGovern Medical School in Houston, US. He obtained his medical degree from Thomas Jefferson University in Philadelphia, trained in Urology at the Mount Sinai School of Medicine in New York City and obtained his fellowship in Urologic Oncology at the MD Anderson Cancer Center in Houston, TX. 

He has dedicated most of his academic career to education, evidence synthesis and guidelines and has contributed research in the fields of prostate cancer genomics, men’s health related prognostics and most recently, novel focal therapy for prostate cancer. He has served on both the American Urological Association and European Association of Urology Guidelines committees, and currently chairs the Methods Committee for the EAU Guidelines.

Michele R. Cole, PharmD, MS, is Director of Medical Managed Markets and Real-World Evidence at Sumitomo Pharma America. With over 20 years of experience, Michele has worked across small, medium and large pharmaceutical companies, making significant contributions in both domestic and global markets.

She has authored more than 40 publications on work and productivity, patient and physician perspectives on medication satisfaction, prescribing patterns, patient journeys, clinical characteristics, cost-effectiveness, budget-impact and predictive models. 

Michele has presented on key topics like Prostate Cancer, Endometriosis, Multiple Sclerosis, Pulmonary Arterial Hypertension, Asthma, COPD, Allergy, In-patient cost savings measures, and payer reimbursement to healthcare reimbursement providers. 

Interests: Real world evidence analysis, market access, Medicaid/Medicare, HTA reimbursement, Prostate Cancer, Endometriosis, Multiple sclerosis, Alzheimer’s disease, Pulmonary Arterial Hypertension, COPD, asthma, allergies, immunology, pain management, geriatrics.

Dr Dan Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.

He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy. 

He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.

Dr Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US. He is the Chief of Staff at the Abramson Cancer Center.

He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.